Novartis: Promacta Gets FDA Breakthrough Therapy Designation For SAA

Novartis (NVS) announced Thursday that the US Food and Drug Administration has granted Breakthrough Therapy designation to Promacta (eltrombopag) for use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic anemia or SAA as a first-line therapy.